How do sponsors know that the commitment will result in more R&D?
Both theory and evidence tell us that investment in R&D rises in line with the expected market size. We have seen similar incentives be effective in stimulating industry response, such as through the Orphan Drug Act and recent UK experience with vaccines for meningitis. Most importantly, we see similar incentives leading to the development of vaccines and drugs for affluent markets.
